This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Jacobson-Kram, D. Articles by Mills, G. PubMed PubMed Citation Articles by Jacobson-Kram, D. Articles by Mills, G. Related Collections Clinical Research Clinical Research: Clinical Trials

Leveraging Exploratory Investigational New Drug Studies to Accelerate Drug Development

Authors' Affiliations: ¹ Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland and ² Perceptive Informatics, Waltham, Massachusetts

Requests for reprints: David Jacobson-Kram, Office of New Drugs, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Phone: 301-796-0175; E-mail: david.jacobsonkram{at}fda.hhs.gov.

Abstract

In 2006, the U.S. Food and Drug Administration published its guide on exploratory investigational new drug (IND) studies with the goal of making the approach to early-stage, pilot clinical trials more flexible within the context of current regulations. The exploratory IND allows sponsors to initiate clinical trials of limited scale with reduced preclinical requirements. These studies may be important vehicles for the conduct of proof-of-principle pharmacodynamic investigations of highly potent molecules, for bioavailability studies that require only a single drug dose to be administered, and for imaging trials that permit critical dosimetry and biodistribution investigations of new molecules. These trials were done with no therapeutic intent and must be followed by traditional dose-escalation investigations that are supported by standard preclinical toxicologic and pharmacologic studies. To the extent that they allow early evaluations of essential drug characteristics that can only be obtained in humans, exploratory IND trials have the potential to limit the cost and improve the development times of new agents.

This article has been cited by other articles:

				G. C. Prendergast Translational Research: Speeding New Concepts between Lab and Clinic Cancer Reviews Online Content, July 1, 2008; 2008(7): 13 - 14. [Full Text] [PDF]

				J. H. Doroshow and R. E. Parchment Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient Clin. Cancer Res., June 15, 2008; 14(12): 3658 - 3663. [Abstract] [Full Text] [PDF]

				A. H. Calvert and R. Plummer The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3664 - 3669. [Abstract] [Full Text] [PDF]

				H. Eliopoulos, V. Giranda, R. Carr, R. Tiehen, T. Leahy, and G. Gordon Phase 0 Trials: An Industry Perspective Clin. Cancer Res., June 15, 2008; 14(12): 3683 - 3688. [Abstract] [Full Text] [PDF]